# Heart Disease and Pregnancy

# **Heart Disease and Pregnancy**

Second Edition

Edited by

Philip J. Steer, BSc MD FRCOG

#### Emeritus Professor, Imperial College London, Academic Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, UK

## Michael A. Gatzoulis, MD PhD FACC FESC

Professor of Cardiology, Congenital Heart Disease and Consultant Cardiologist, Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, and the National Heart & Lung Institute, Imperial College London, UK





University Printing House, Cambridge CB2 8BS, United Kingdom

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning and research at the highest international levels of excellence.

www.cambridge.org Information on this title: www.cambridge.org/9781107095946

© Cambridge University Press (2006) 2016

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published: 2006 by RCOG Press Second edition Year 2016

Printed in the United Kingdom by TJ International Ltd. Padstow Cornwall

A catalog record for this publication is available from the British Library

Library of Congress Cataloging in Publication data

Names: Steer, Philip J., editor. | Gatzoulis, Michael A., editor. Title: Heart disease and pregnancy / edited by Philip J. Steer, Philip J. Steer, BSc MD FRCOG, Emeritus Professor, Imperial College London, Academic Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, UK, Michael A. Gatzoulis, MD PhD FACC FESC, Professor of Cardiology, Congenital Heart Disease and Consultant Cardiologist Adult Congenital Heart Centre and Centre for Pulmonary Hypertension Royal Brompton Hospital, and the National Heart & Lung Institute, Imperial College, London, UK. Description: Second edition. | Cambridge, United Kingdom : Cambridge University Press, 2016. | Includes bibliographical references and index. Identifiers: LCCN 2015041127 | ISBN 9781107095946 (hardback) Subjects: LCSH: Heart diseases in pregnancy. Classification: LCC RG580.H4 H42 2016 | DDC 618.3/61–dc23 LC record available at http://lccn.loc.gov/2015041127

ISBN 978-1-107-09594-6 Hardback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

.....

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

## Contents

List of contributors vii Preface ix Consensus statements x

# Section 1 – Pregnancy Counseling and Contraception

- Preconception counseling for women with cardiac disease 1 Sarah Vause, Sara Thorne, and Bernard Clarke
- 2. Contraception in women with heart disease 6 Mandish K. Dhanjal

Section 2 – Antenatal Care: General Considerations

- Cardiovascular changes in normal pregnancy 19 Mark Johnson and Katherine von Klemperer
- Antenatal care of women with cardiac disease: An obstetric perspective 29 Matthew Cauldwell, Martin Lupton, and Roshni R. Patel
- 5. Antenatal care of women with cardiac disease: A cardiac perspective 36 Fiona Walker
- **6.** Cardiac monitoring during pregnancy **43** Henryk Kafka, Sonya V. Babu-Narayan, and Wei Li
- **7. Cardiac drugs in pregnancy 53** Asma Khalil, Gerhard-Paul Diller, and Patrick O'Brien
- 8. Surgical and catheter intervention during pregnancy in women with heart disease 65 Henryk Kafka, Hideki Uemura, and Anselm Uebing

## Section 3 – Antenatal Care: Fetal Considerations

- 9. Antenatal diagnosis of congenital heart disease 84
   Victoria Jowett and Julene S. Carvalho
- 10. Fetal care and surveillance in women with congenital heart disease 96Christina K. H. Yu and Tiong Ghee Teoh

# Section 4 – Antenatal Care: Specific Maternal Conditions

- Management of women with prosthetic heart valves during pregnancy 106 Carole A. Warnes
- 12. Management of aortopathies, including Marfan syndrome and coarctation, in pregnancy 115 Lorna Swan
- 13. Management of mitral and aortic stenosis in pregnancy 125Sara Thorne
- 14. Management of right heart lesions in pregnancy 131 Annette Schophuus Jensen, Lars Søndergaard, and Anselm Uebing
- 15. Management of pulmonary hypertension in pregnancy 144 David G. Kiely, Charlie A. Elliot, Victoria J. Wilson, Saurabh V. Gandhi, and Robin Condliffe

#### Contents

- 16. Management of cardiomyopathies in pregnancy 160Catherine Nelson-Piercy and Catherine Head
- 17. Management of ischemic heart disease in pregnancy 174Jolien W. Roos-Hesselink and Iris M. van Hagen
- 18. Management of maternal cardiac arrhythmias in pregnancy 180 Koichiro Niwa and Chizuko Kamiya
- 19. Management of maternal endocarditis in pregnancy 191Stephanie L. Curtis and Graham Stuart
- 20. Management of women with heart and lung transplantation in pregnancy 199
  Coralie Blanche and Maurice Beghetti

### Section 5 – Intrapartum Care

**21. Pregnancy and cardiac disease: Peripartum aspects 208** David Alexander, Kate Langford, and Martin Dresner

## Section 6 – Postpartum Care

- 22. Management of the puerperium in women with heart disease 218 Margaret Ramsay
- 23. Impact of pregnancy on long-term outcomes in women with heart disease 227 Henryk Kafka and Natali A. Y. Chung
- 24. Long-term outcome of pregnancy with heart disease 234 Carole A. Warnes

Appendix A: New York Heart Association classification of cardiovascular disease 240 Appendix B: Antenatal care pathway 241 Index 255

*The colour plate section appears between pages 154 and 155.* 

## List of contributors

David Alexander FRCA

Department of Anaesthetics, Royal Brompton Hospital, London, UK

**Sonya V. Babu-Narayan BSc MRCP PhD** Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and Imperial College, London, UK

#### Maurice Beghetti MD

Pediatric Cardiology Unit, Children's University Hospital, Geneva, Switzerland

**Coralie Blanche MD** Adult Congenital Heart Disease Centre, Royal Brompton Hospital, London, UK

**Julene S. Carvalho MD PhD FRCPCH** Royal Brompton Hospital and Fetal Medicine Unit, St

George's University Hospitals, St George's University of London, London, UK

#### Matthew Cauldwell BSc MRCOG MRCP MEd

Department of Obstetrics & Gynaecology, Chelsea & Westminster Hospital, London, UK

#### Natali A.Y. Chung MD FRCP

Department of Cardiology, Guy's and St Thomas' NHS Foundation Trust, London, UK

#### Bernard Clarke BSc MD FRCP FESC FACC FRAeS FRCOG(Hon)

Department of Cardiology, Manchester Royal Infirmary and Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK

#### Robin Condliffe MD

Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK

#### Stephanie L. Curtis BSc (Hons) MD FRCP

Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

#### Mandish K. Dhanjal BSc MRCP FRCOG

Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust, London, UK

#### Gerhard-Paul Diller MD PhD MSc

Division of Adult Congenital & Valvular Heart Disease, University Hospital Münster, Münster, Germany

#### Martin Dresner FRCA

Department of Anaesthetics, Leeds Royal Infirmary, Leeds, UK

**Charlie A. Elliot FRCP** Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK

#### Saurabh V. Gandhi MD MRCOG

Department of Obstetrics & Gynaecology, Royal Hallamshire Hospital, Sheffield, UK

#### Catherine Head MS PhD FRCP

Department of Cardiology, Guy's and St Thomas' NHS Foundation Trust, London, UK

#### Annette Schophuus Jensen

Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark

#### Mark Johnson MRCP PhD MRCOG

Department of Obstetrics & Gynaecology, Chelsea & Westminster Hospital, London, UK

#### Victoria Jowett MRCPCH

Royal Brompton Hospital and Centre of Fetal Care, Queen Charlotte's & Chelsea Hospital, Imperial College Healthcare NHS Trust, London, UK

#### Henryk Kafka MD FRCPC FACC

Division of Cardiology, Queen's University, Kingston, Canada

#### Chizuko Kamiya MD

Department of Perinatology, National Cardiovascular Center, Osaka, Japan

List of contributors

#### Asma Khalil MD MRCOG MSc

St George's Medical School, University of London, London, UK.

**David G. Kiely MD FCCP** Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK

#### Kate Langford MA MD MBA FRCOG

Department of Obstetrics & Gynaecology, Guy's and St Thomas' Hospitals NHS Trust, London, UK

**Wei Li MBBS MD PhD FESC FACC** Department of Echocardiography, Royal Brompton Hospital, London, UK

### Martin Lupton MA MRCOG

Department of Obstetrics & Gynaecology, Chelsea & Westminster Hospital, London, UK

#### Catherine Nelson-Piercy MA FRCP FRCOG

Women's Health Academic Centre, St Thomas' Hospital, London, UK

#### Koichiro Niwa MD PhD FACC FAHA FJCC

Cardiovascular Center, St Luke's International Hospital, Tokyo, Japan

**Patrick O'Brien FRCOG FFSRH FICOG** Institute for Women's Health, University College London Hospitals, London, UK

#### Roshni R. Patel MSc MRCOG

Department of Obstetrics & Gynaecology, Chelsea & Westminster Hospital, London, UK

#### Margaret Ramsay MA MD MRCP FRCOG

Department of Obstetrics and Fetomaternal Medicine, Nottingham University Hospitals, Queen's Medical Centre Campus, Nottingham, UK

**Jolien W. Roos-Hesselink MD PhD** Department of Cardiology, Erasmus Medical Center, Rotterdam, Netherlands

#### Lars Søndergaard MD

Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark

#### **Graham Stuart FRCP FRCPCH**

Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

#### Lorna Swan FRCP MD

Adult Congenital Heart Disease Unit, Royal Brompton Hospital, London, UK

#### Tiong Ghee Teoh MD FRCOG

Department of Obstetrics & Gynaecology, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK

#### Sara Thorne MD FRCP

Department of Cardiology, University Hospital Birmingham, Birmingham, UK

#### Anselm Uebing MD PhD

Adult Congenital Heart Disease Centre, Royal Brompton Hospital, London, UK

#### Hideki Uemura MD MPhil FRCS

Department of Cardiothoracic Surgery, Royal Brompton Hospital, London, UK; Congenital Heart Disease Center, Nara Medical University, Nara, Japan

#### Iris M. van Hagen MD

Department of Cardiology, Erasmus Medical Center, Rotterdam, Netherlands

#### Sarah Vause MD FRCOG

St Mary's Hospital, Manchester, UK

Katherine von Klemperer MRCP Royal Brompton Hospital, London, UK

#### Fiona Walker FRCP FESC

Lead for Pregnancy & Heart Disease Program, UCLH and Barts Health NHS Trust, London, UK

#### Carole A. Warnes MD FRCP

Adult Congenital Heart Disease Clinic, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA

#### Victoria J. Wilson FRCA

Department of Anaesthesia & Critical Care, Royal Hallamshire Hospital, Sheffield, UK

#### Christina K. H. Yu BSc MD MRCOG

Department of Obstetrics & Gynaecology, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK

## Preface

Since the turn of the twenty-first century, cardiac disease has become the leading medical cause of death in relation to pregnancy in the United Kingdom. In response to this, the meetings committee of the Royal College of Obstetricians and Gynaecologists in London put together an international study group of 28 obstetricians, cardiologists, anesthetists and other experts in related fields to discuss this challenge to maternal health. The group met on February 13–15, 2006 at the RCOG in London, and out of this meeting came the first edition of *Heart Disease and Pregnancy*, published in the same year. Both the first and second printing sold out, so clearly the book was meeting a need.

From 2010 onwards, there were increasing requests for an update to a volume that so many people had found useful. Unfortunately, the RCOG no longer funds such activities; study groups now concentrate on developing research proposals, and the publishing department has been closed, and its booklist transferred to Cambridge University Press. Fortunately, we were able to persuade Cambridge University Press of the need for a second edition, and we are grateful to Nick Dunton for taking our proposals forward to success. In addition, one of us (MAG) runs a regular international meeting on congenital heart disease, and he was able to arrange a consensus session at one of the meetings (held at the Royal College of Surgeons in September 2014) where many of the original participants (and some new ones) gathered together to update the consensus statements.

Consensus statements are necessary because there is a paucity of randomized trials in relation to heart disease in pregnancy, and therefore clinical guidelines rely heavily upon expert opinion. Funding for randomized trials or international collaborative studies is difficult to obtain because globally, maternal and child health have a low political priority. In addition, the increasing number of international regulations applying to any studies involving drug therapy make randomized trials extremely expensive, especially when the conditions studied are individually relatively uncommon. However, the growing number of surviving women with corrected or ameliorated congenital heart disease, and the increasing attempts to improve maternal health globally, means that guidelines are required for the growing number of centers dealing with pregnant women with heart disease.

We are grateful to those authors who have updated their previous chapters, and there have been a considerable number of new contributors, who have looked at things afresh, and sometimes contributed entirely new chapters (for example, on transplantation). The chapters are laid out in a way that we hope readers will find intuitive, starting with prepregnancy counseling and contraception, moving through the antenatal period to delivery and the puerperium, and finishing with long-term outcome. There is some overlap between chapters, for example the physiological changes of pregnancy are often recapped at the beginning. The purpose of this is to make each chapter comprehensible in its own right, both for easy initial reading, and for rapid revision. We have done our best to make sure that there is no significant conflict between the content of the various chapters.

In the first edition, we had a special section at the end for the consensus statements, both "overarching" and specific to individual chapters. In response to feedback from the many readers who felt the consensus statements were particularly useful, we have now put the overarching statements right at the front of the book, and those that are more specifically condition related are included at the beginning of their appropriate chapters as "practical practice points." We hope that this innovation will make the book even more useful than the first edition.

## **Consensus statements**

The following consensus statements were drafted at a face to face meeting at the Royal College of Surgeons (London) on September 30, 2014, and subsequently agreed by email. They are followed by the list of participants in the meeting, and a photograph of them on the steps of the Royal College of Surgeons.

## Definitions

- 1. Multidisciplinary Team (MDT). The core members of the MDT should be appropriately trained obstetricians, cardiologists, and anesthetists, and the wider team who should also be involved in care when appropriate may include midwives, neonatologists, intensivists, obstetric physicians, hematologists, specialist nurses and geneticists.
- 2. A tertiary unit is defined as a hospital (or group of hospitals) able to provide combined obstetric, cardiological, anesthetic and cardiac surgical expertise in the care of women with heart disease. Any tertiary center caring for pregnant women with heart disease should have facilities for prolonged high-level maternal surveillance with direct access to adult critical care facilities.

## **Overarching consensus views**

### General

1. There should be national and international registries for the collection of data on pregnancy in women with heart disease. These data should be collected centrally to enable a more detailed analysis of risk factors for poor pregnancy and long-term outcomes (including maternal survival and infant disability). Such information would greatly improve the counseling of women with heart disease.

- 2. There should be recognized networks for the provision of care for women with both acquired and congenital heart disease and appropriate referral links should be established. These will need to be specifically funded as the care of these women cannot be provided from routine obstetric and cardiac resources.
- 3. If any pregnant or postpartum woman has unexpected and persistent cardiorespiratory symptoms she should have thorough evaluation of possible cardiovascular causes such as cardiomyopathy, acute coronary syndrome, aortic dissection and pulmonary embolism.

## Preconception

- A proactive approach to preconception counseling should be started in adolescence (at age 12–15 years, depending on individual maturity) and should include advice on safe and effective contraception. Comprehensive advice should be given at the appropriate age and not delayed until transfer to the adult cardiological services.
- 2. All women of reproductive age with congenital or acquired heart disease should have access to specialized multidisciplinary preconception counseling with regular reevaluation to enable them to make a fully informed choice about pregnancy.
- 3. When assisted conception is being planned, the advice of the MDT should be sought before any such treatment is commenced.
- 4. In counseling women about motherhood, alternatives to the woman carrying the baby herself can be considered (for example surrogacy or adoption).
- 5. Women with a family history of inherited cardiac conditions should be screened before pregnancy.

**Consensus statements** 

- 6. Any cardiac surgical interventions in women of childbearing age should take into account the effect they may have on pregnancy. For example, because of the risks associated with prosthetic mechanical valves in pregnancy, consideration should be given to valve repair or using tissue valves for valve replacement.
- 7. Contraceptive choice for women with heart disease should be tailored to the particular patient, taking into account any increased risks of thrombosis or infection associated with the various contraceptive methods and their interaction with the various heart lesions or drugs being taken.

## Antenatal care

- 1. Once women with heart disease are pregnant, they should be referred to the MDT as soon as possible. The timing and frequency of follow-up visits should be determined by the MDT. Direct self-referral should also be allowed, to avoid delays.
- 2. Medication should be reviewed and adjusted as necessary.
- 3. The threshold for starting thromboprophylaxis should be determined by the MDT.
- 4. Thrombolysis may cause bleeding from the placental site but should be given in women with life-threatening thrombotic disease.
- 5. Following assessment by the MDT, care can be arranged at a local hospital or tertiary unit (where the MDT is based), according to the complexity of the heart disease, the risk assessment and the locally available facilities and expertise. Shared care between the local and tertiary hospitals may be appropriate, in which case a detailed plan of care should be documented and accessible to all care providers.
- 6. A copy of the plan should be carried by the woman herself, so it is available in an emergency to care providers other than her usual team.
- 7. Women with congenital heart disease should be offered fetal echocardiography.
- 8. Tertiary units should offer a hotel facility to enable women who live some distance from the hospital to stay on site, to avoid (a) a delay in receiving appropriate care when they go into labor and (b) the need to induce labor solely to avoid this risk.

### Intrapartum care

- 1. Management of intrapartum care should be supervised by a team experienced in the care of women with heart disease (obstetrician, anesthetist and midwife), with a cardiologist or appropriately experienced obstetric physician readily available.
- 2. A clear plan for management of delivery and the puerperium in women with heart disease should be established in advance, be well documented and be distributed widely (including to the woman herself) so that all personnel likely to be involved in the woman's intrapartum and postpartum care are fully informed. It is recommended that the woman should carry her own notes (or at least a copy of them) at all times. There should be clear arrangements for contacting the MDT in case of an emergency.
- 3. Vaginal delivery is the preferred mode of delivery over cesarean section for most women with heart disease—whether congenital or acquired—unless obstetric or specific cardiac considerations determine otherwise. This can be facilitated where appropriate by the use of regional anesthesia and assisted vaginal delivery.
- 4. Induction of labor may be appropriate, to optimize the timing of delivery in relation to anticoagulation and the availability of specific medical staff or because of deteriorating maternal cardiac function.
- 5. In the management of the third stage of labor in women with heart disease, low-dose oxytocin infusions are safer than bolus doses of oxytocin, which can cause hypotension. Ergometrine is best avoided if systemic hypertension is a concern. Misoprostol is an effective uterotonic although it can cause problems such as hyperthermia.
- 6. When planning care, specific instructions should be recorded regarding intrapartum antibiotic prophylaxis. There is no evidence that prophylactic antibiotics prevent endocarditis in an uncomplicated vaginal delivery. However, prophylactic antibiotic cover should be given to women undergoing an operative delivery, and to women at increased risk of infectious endocarditis, such as those with mechanical valves or a history of previous endocarditis and to women before any intervention that is likely to be associated with significant or recurrent bacteremia. The possibility of endocarditis should always be borne in mind.

**Consensus statements** 

### Postpartum care

1. High-level maternal surveillance is required until the main hemodynamic challenges following delivery have passed. Multidisciplinary surveillance should be maintained until it is judged the woman is well enough to leave hospital. Follow-up assessment should be arranged by the MDT. Contraceptive advice must be given.

## List of participants in the consensus meeting

Adamson	Dawn	Cardiologist	Coventry
Chung	Natali	Cardiologist	Guy's and St Thomas'
Clarke	Bernard	Cardiologist	Manchester
Curtis	Stephanie	Cardiologist	Bristol
Dhanjal	Mandish	Obstetrician	Queen Charlotte's Hospital
Gatzoulis	Michael	Cardiologist	Imperial College London
Head	Cathy	Cardiologist	Guy's and St Thomas'
Jensen	Annette	Cardiologist	Copenhagen, Denmark
Johnson	Mark	Obstetrician	Imperial College London
Kamiya	Chizuko	Cardiologist	Osaka, Japan
Li	Wei	Cardiologist	Royal Brompton Hospital
Nelson-Piercy	Catherine	Obstetric Physician	Guy's and St Thomas'
Patel	Roshni	Obstetrician	Chelsea and Westminster Hospital
Ramsay	Margaret	Obstetrician	Nottingham
Roos-Hesslink	Jolien	Cardiologist	Rotterdam, Netherlands
Søndergaard	Lars	Cardiologist	Copenhagen, Denmark
Steer	Philip	Obstetrician	Imperial College London
Van Hagen	lris	Cardiologist	Rotterdam, Netherlands
Vause	Sarah	Obstetrician	Manchester
Van Klanne avar	Kate	Cardiologist	Royal Brompton Hospital
Von Klemperer	Rate	Cardiologist	noyarbioinptoinnospitai
Warnes	Carole	Cardiologist	Mayo Clinic, USA
		3	

Consensus statements

# Picture of the participants in the consensus meeting



#### Figure X.1. Front row, left to right

Michael Gatzoulis, Philip Steer, Mandish Dhanjal, Bernard Clarke, Margaret Ramsay, Natali Chung, Sarah Vause, Jolien Roos-Hesslink, Cathy Nelson-Piercy, Stephanie Curtis

#### Behind, from left

Mark Johnson, Roshni Patel, Iris van Hagen, Kate von Klemperer, Chrissie Yu, Dawn Adamson, (partially obscured, Annette Jensen), Carole Warnes, Lars Søndergaard, Kamiya Chizuko, Cathy Head, Wei Li